SEC Filing Summary
Business Context and Reporting Period
Haymaker Acquisition Corp. III filed a Form 8-K dated December 13, 2021, under Item 7.01 to furnish materials relating to its proposed business combination with BioTe Holdings, LLC (BioTE). Management of Haymaker and BioTE conducted a joint webcast, and the webcast transcript was furnished as Exhibit 99.1.
The transaction is governed by a Business Combination Agreement involving Haymaker, its sponsor, BioTE, BioTe Management, LLC, Dr. Gary Donovitz, and the members’ representative. The proposed transaction would result in a combined public company expected to operate under the Biote name; the filing does not provide complete transaction terms or final closing details.
Financial Metrics and Capitalization
- The filing does not provide revenue, profit, cash flow, margins, balance sheet, debt, liquidity, or operating performance metrics for Haymaker or BioTE.
- The filing references the expected amount of transaction cash, minimum cash requirements, potential stockholder redemptions, and proposed Truist debt financing, but does not provide clear dollar amounts or finalized financing terms in the supplied text.
- No historical or pro forma financial statements are included in this filing.
Material Changes Versus the Prior Comparable Period
The filing reports a transaction-related development rather than periodic operating results. The material change is the public webcast and related disclosure concerning the proposed BioTE business combination. No comparable-period financial data or operating changes are presented.
Guidance, Outlook, Risks, and Unusual Items
Management’s webcast and related materials include forward-looking statements concerning the transaction, BioTE’s markets and services, expected growth, future results, capital expenditures, competitive advantages, and business opportunities. The filing does not provide definitive financial guidance or clearly quantified forecasts in the supplied text.
- Closing remains subject to stockholder approval, satisfaction of minimum cash requirements after redemptions, governmental and regulatory approvals, and other customary conditions.
- The transaction may not close by Haymaker’s business-combination deadline, and any required extension may not be obtained.
- Risks include termination of the agreement, transaction-related disruption, litigation, inability to maintain exchange listing, competitive and regulatory changes, COVID-19-related downturns, transaction costs, failure to realize anticipated benefits, and inability to complete the Truist debt financing.
- BioTE-specific risks include regulatory scrutiny of pharmacy compounding, health care fraud and abuse, HIPAA and data privacy matters, supply-chain constraints, competition, limited operating history, dependence on physicians and key personnel, third-party manufacturing, intellectual property, litigation, capital needs, and potential dilution.
- The Item 7.01 information and webcast transcript are furnished, not filed, for purposes of Section 18 of the Exchange Act and are generally not incorporated by reference except where expressly stated.
Important Facts for Investors to Verify
- Review the definitive proxy statement and related SEC filings for the complete transaction structure, valuation, ownership, dilution, redemption assumptions, and closing conditions.
- Verify BioTE’s historical and projected financial statements, including revenue, profitability, cash flow, debt, liquidity, and adjusted or non-GAAP measures.
- Confirm the status, amount, and conditions of the proposed Truist debt financing and the minimum cash requirement.
- Assess the potential impact of public-stockholder redemptions and any additional financing on the combined company’s capitalization.
- Review regulatory, litigation, pharmacy-compounding, health care compliance, cybersecurity, and supply-chain disclosures before relying on management’s outlook.